GT Biopharma, Inc. Issues Form 8-K: Restatement of Financial Results for 2025 Due to Misclassification of Greenshoe Rights

Key Highlights:

• GT Biopharma, Inc. (Nasdaq: GTBP) has announced a significant restatement of its financial statements for the quarters ended June 30, 2025 and September 30, 2025.
• The restatement arises from an error in the accounting classification of certain stock purchase rights (“Greenshoe Rights”) related to the company’s May 2025 private placement of Series L 10% Convertible Preferred Stock.
• The misclassification could have resulted in previously issued financial statements being unreliable and may have material implications for the company’s reported losses and equity position.

Details of the Restatement

During the preparation of its Annual Report on Form 10-K for the year ended December 31, 2025, GT Biopharma, in consultation with its independent registered public accounting firm Weinberg & Company, P.A., identified a misclassification related to the Greenshoe Rights issued in May 2025. Specifically, the redemption provisions in the Series L Preferred Stock could require cash settlement in certain circumstances outside the company’s control. As a result, under the FASB’s ASC 480 “Distinguishing Liabilities from Equity,” the Greenshoe Rights should have been classified as liabilities, not equity.

On March 1, 2026, the audit committee determined that the company’s previously issued quarterly financial statements for the periods ended June 30, 2025 and September 30, 2025 “may no longer be relied upon.” The company will restate these financial statements and file amended Forms 10-Q/A as soon as practicable, and has also included restated interim consolidated financial data within its 2025 Form 10-K.

Impact on Financial Results

Restated Balance Sheets:

• June 30, 2025: The restatement reduced total stockholders’ equity from \$2.86 million (originally reported) to a deficit of \$(25.88) million. The adjustment was primarily due to an increase in the accumulated deficit by \$(28.74) million, reflecting the reclassification of Greenshoe Rights liability. Total assets remained unchanged at \$7.12 million.
• September 30, 2025: The restatement similarly reduced total stockholders’ equity from \$3.0 million (originally reported) to a deficit of \$(15.74) million. The accumulated deficit increased by \$(17.32) million, with total assets unchanged at \$4.32 million.

Restated Income Statements:

• For the three months ended June 30, 2025:
  • Net loss increased dramatically from \$(1.43) million as originally reported, to a restated \$(30.17) million, due to a \$(28.74) million adjustment.
  • Net loss attributable to common stockholders per share increased from \$(0.55) to \$(10.92).
  • No impact on loss from operations, but the adjustment reflects the liability treatment for the Greenshoe Rights.
• For the three months ended September 30, 2025:
  • Net loss was restated from \$(3.11) million to \$8.30 million, reflecting a \$11.41 million gain from the change in fair value of the Greenshoe Rights liability.
  • Net loss attributable to common stockholders per share changed from \$(0.83) to \$1.04.
• For the six months ended June 30, 2025:
  • Net loss increased from \$(5.32) million to \$(22.65) million after restatement.
  • Net loss attributable to common stockholders per share increased accordingly.
• For the nine months ended September 30, 2025:
  • Net loss increased from \$(5.55) million to \$(26.93) million after restatement.
  • Net loss per share increased from \$(1.84) to \$(8.90).

The restatement had a significant impact on the company’s reported net loss and equity, but did not impact net cash provided by operating activities, net cash used in investing activities, or net cash provided by (used in) financing activities for any of the applicable periods.

Shareholder and Investor Implications

• Material Weakness: This restatement reflects a material weakness in the company’s internal controls over financial reporting, particularly in evaluating complex equity and liability transactions. Investors should be aware that this may subject the company to higher scrutiny from regulators and may affect market perception.
• Potential Volatility: The sharp increase in reported net losses and the shift from positive equity to a significant equity deficit could be considered price sensitive and may negatively impact the company’s share price in the near term.
• Ongoing Compliance: The company is taking steps to amend its filings and remain in compliance with SEC requirements. However, the restatement may raise questions about the reliability of past and future financial statements until the company demonstrates improved controls.
• Emerging Growth Company Status: GT Biopharma is not an emerging growth company under SEC definitions, meaning it is subject to the full range of reporting and compliance requirements of the Securities Exchange Act.

Conclusion

Action for Investors: Investors should closely monitor GT Biopharma’s forthcoming amended filings and any additional disclosures regarding internal controls and financial reporting. The magnitude of the restated losses and equity deficit is material and could influence investment decisions, institutional holdings, and market confidence. This restatement is a key development for shareholders and is likely to result in share price volatility.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The author and publisher are not responsible for any actions taken based on the information provided above.

View GT Biopharma, Inc. Historical chart here